Use and persistence of lipid-lowering therapy in patients with severe hypercholesterolemia: A prospective study

Clin Investig Arterioscler. 2021 Nov-Dec;33(6):308-313. doi: 10.1016/j.arteri.2021.07.003. Epub 2021 Oct 14.
[Article in English, Spanish]

Abstract

Introduction: Statins are the first line of treatment in patients with severe hypercholesterolemia (SH). However, despite the knowledge regarding its effectiveness and security for preventing cardiovascular diseases, treatment is a major challenge.

Material and methods: A prospective observational study was conducted by telephone survey to determine cardiovascular risk factors, annual monitoring, statins use and persistence and new-onset cardiovascular events (CVE) after 5 years in patients with SH including in a program for detection of familial hypercholesterolemia.

Results: 115 participants were analysed, the median age was 56 ±10 being 74% females. 63.4% of women and 43% of men had been correctly controlled in the last year. Patients on lipid lowering drugs stratified by sex was 38.8% in women and 26.7% in men, however, only 22 participants (31.8%) were persistence with statins since 2015.Overall, 48% of the patients presented a CVE and 3.4% died. Multivariate analysis did not reveal predictors for CVE.

Conclusions: In our population with SH we found a high risk to present a CVE and a dramatic low use and persistence with the treatment.

Keywords: Adherence; Adherencia; Cardiovascular disease; Enfermedad cardiovascular; Hypercholesterolemia; Lipid-lowering therapy; Persistence; Persistencia, Hipercolesterolemia; Tratamiento hipolipidemiante.

Publication types

  • Observational Study

MeSH terms

  • Aged
  • Cardiovascular Diseases* / epidemiology
  • Cardiovascular Diseases* / etiology
  • Cardiovascular Diseases* / prevention & control
  • Cholesterol, LDL
  • Female
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors* / therapeutic use
  • Hypercholesterolemia* / drug therapy
  • Hypercholesterolemia* / epidemiology
  • Hyperlipoproteinemia Type II*
  • Male
  • Middle Aged
  • Prospective Studies

Substances

  • Cholesterol, LDL
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors